ProSTAR: A Phase 1b/2 Study of CPI-1205 a Small Molecule Inhibitor of EZH2 Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

Brief description of study

This Phase 1b/2 trial is testing a drug, CPI-1205, that targets the EPIGENETICS of metastatic Castration Resistant Prostate Cancer. The main goal of the study is to find out if CPI-1205 can be an effective anti-cancer treatment for men with metastatic castration resistant prostate cancer (CRPC). CPI-1205 will be administered alone or with cobicistat, combined with enzalutamide or abiraterone/prednisone.

Clinical Study Identifier: s18-00024 Identifier: NCT03480646
Principal Investigator: David R. Wise
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.